Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164
Dung T. Le*, Tae Won Kim, Eric van Cutsem, Ravit Geva, Dirk Jäger, Hiroki Hara, Matthew Burge, Bert O’Neil, Petr Kavan, Takayuki Yoshino, Rosine Guimbaud, Hiroya Taniguchi, Elena Elez, Salah Eddin Al-Batran, Patrick M. Boland, Todd Crocenzi, Chloe E. Atreya, Yi Cui, Tong Dai, Patricia MarinelloLuis A. Diaz, Thierry André
Research output: Contribution to journal › Article › peer-review
738Scopus
citations
Fingerprint
Dive into the research topics of 'Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164'. Together they form a unique fingerprint.